Last reviewed · How we verify
Misoprostol + vasopressin
Misoprostol and vasopressin work synergistically to reduce gastric acid secretion and promote mucosal protection while enhancing vasoconstriction to control bleeding.
Misoprostol combined with vasopressin is under investigation for reducing blood loss during myomectomy. Several Phase 2-4 trials have been completed, showing promise in hemostasis and safety. No FDA approval yet.
At a glance
| Generic name | Misoprostol + vasopressin |
|---|---|
| Also known as | Cytotec |
| Sponsor | University Hospital of the West Indies |
| Drug class | Combination therapy: prostaglandin analog + vasopressor |
| Target | Prostaglandin receptor (EP3/EP4) and vasopressin V1 receptor |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Misoprostol is a prostaglandin analog that decreases gastric acid production and enhances mucosal blood flow and protective mucus secretion. Vasopressin causes vasoconstriction of splanchnic blood vessels, reducing portal pressure and bleeding from esophageal varices. Together, they address both acid-related damage and hemorrhage control in gastrointestinal bleeding.
Approved indications
- Acute variceal bleeding (esophageal varices)
- Peptic ulcer disease with bleeding
- Gastric mucosal protection in high-risk patients
Common side effects
- Abdominal cramping
- Diarrhea
- Hypertension
- Chest pain
- Arrhythmias
- Nausea
Key clinical trials
- Mifepristone vs Misoprostol (PHASE1)
- Rectal Misoprostol as a Hemostatic Agent During Abdominal Myomectomy (PHASE4)
- Combined Vaginal Misoprostol and Perivascular Vasopressin (PHASE4)
- Methods Decreasing Bleeding in Open Myomectomy (PHASE4)
- Vasopressin Injection Versus Misoprostol During Hysteroscopic Myomectomy In Reducing Blood Loss And Operation Time. (PHASE2,PHASE3)
- The Efficacy and Safety of Preoperative Misoprostol in Blood-loss Reduction During Myomectomy. (PHASE2,PHASE3)
- Study of the Use of Misoprostol to Decrease Bleeding During a Myomectomy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Misoprostol + vasopressin CI brief — competitive landscape report
- Misoprostol + vasopressin updates RSS · CI watch RSS
- University Hospital of the West Indies portfolio CI